Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617–627.
Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H-U. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 2012; 21: 169–184.
Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 7: 137–151.
Martinowich K, Jimenez DV, Zarate Ca, Manji HK. Rapid antidepressant effects: moving right along. Mol Psychiatry 2013; 18: 856–863.
Thornalley PJ. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification—a role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol 1996; 27: 565–573.
Distler MG, Plant LD, Sokoloff G, Hawk AJ, Aneas I, Wuenschell GE et al. Glyoxalase 1 increases anxiety by reducing GABA A receptor agonist methylglyoxal. J Clin Invest 2012; 122: 2306–2315.
Benton CS, Miller BH, Skwerer S, Suzuki O, Schultz LE, Cameron MD et al. Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains. Psychopharmacology 2012; 221: 297–315.
Yang Y, Yang D, Tang G, Zhou C, Cheng K, Zhou J et al. Proteomics reveals energy and glutathione metabolic dysregulation in the prefrontal cortex of a rat model of depression. Neuroscience 2013; 247: 191–200.
Patki G, Solanki N, Atrooz F, Allam F, Salim S. Depression, anxiety-like behavior and memory impairment are associated with increased oxidative stress and inflammation in a rat model of social stress. Brain Res 2013; 1539: 73–86.
Hovatta I, Tennant RS, Helton R, Marr Ra, Singer O, Redwine JM et al. Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. Nature 2005; 438: 662–666.
Williams R, Lim JE, Harr B, Wing C, Walters R, Distler MG et al. A common and unstable copy number variant is associated with differences in Glo1 expression and anxiety-like behavior. PLoS ONE 2009; 4: e4649.
Kendler KS, Gardner CO, Gatz M, Pedersen NL. The sources of co-morbidity between major depression and generalized anxiety disorder in a Swedish national twin sample. Psychol Med 2007; 37: 453–462.
Demirkan A, Penninx BWJH, Hek K, Wray NR, Amin N, Aulchenko YS et al. Genetic risk profiles for depression and anxiety in adult and elderly cohorts. Mol Psychiatry 2011; 16: 773–783.
Kent JM, Mathew SJ, Gorman JM. Molecular targets in the treatment of anxiety. Biol Psychiatry 2002; 52: 1008–1030.
El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008; 205: 2409–2417.
McMurray KMJ, Sidhu PS, Cook JM, Arnold LA, Palmer AA. Genetic and pharmacological manipulation of glyoxalase 1 regulates voluntary ethanol consumption in mice. Addict Biol 2017; 22: 381–389.
Kawatani M, Okumura H, Honda K, Kanoh N, Muroi M, Dohmae N et al. The identification of an osteoclastogenesis inhibitor through the inhibition of glyoxalase I. Proc Natl Acad Sci U S A 2008; 105: 11691–11696.
Kanoh N, Suzuki T, Kawatani M, Katou Y, Osada H, Iwabuchi Y. Dual structure-activity relationship of osteoclastogenesis inhibitor methyl gerfelin based on teg scanning. Bioconjug Chem 2013; 24: 44–52.
Opal MD, Klenotich SC, Morais M, Bessa J, Winkle J, Doukas D et al. Serotonin 2C receptor antagonists induce fast-onset antidepressant effects. Mol Psychiatry 2013; 19: 1106–1114.
Dulawa SC, Holick KA, Gundersen B, Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 2004; 29: 1321–1330.
Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005; 29: 571–625.
Jiao J, Opal MD, Dulawa SC. Gestational environment programs adult depression-like behavior through methylation of the calcitonin gene-related peptide gene. Mol Psychiatry 2012; 18: 1–8.
Cryan JF, Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 2005; 4: 775–790.
Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci 2012; 35: 47–56.
Browne Ca, Lucki I. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol 2013; 4: 1–18.
Jiao J, Nitzke AM, Doukas DG, Seiglie MP, Dulawa SC. Antidepressant response to chronic citalopram treatment in eight inbred mouse strains. Psychopharmacology 2011; 213: 509–520.
Jarosik J, Legutko B, Unsicker K, von Bohlen Und, Halbach O. Antidepressant-mediated reversal of abnormal behavior and neurodegeneration in mice following olfactory bulbectomy. Exp Neurol 2007; 204: 20–28.
Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002; 23: 238–245.
Dulawa SC, Hen R. Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci Biobehav Rev 2005; 29: 771–783.
Marcia JR, Stephanie CD. Identifying fast-onset antidepressants using Rodent models. Mol Psychiatry 2017 (in press).
Klumpers UMH, Veltman DJ, Drent ML, Boellaard R, Comans EFI, Meynen G et al. Reduced parahippocampal and lateral temporal GABAA-[11C]flumazenil binding in major depression: preliminary results. Eur J Nucl Med Mol Imaging 2010; 37: 565–574.
Sanacora G, Mason GF, Rothman DL, Krystal JH. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 2002; 159: 663–665.
Möhler H. The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology 2012; 62: 42–53.
Kalueff AV, Nutt DJ. Role of GABA in anxiety and depression. Depress Anxiety 2007; 24: 495–517.
Ahmed El zahaf N, Salem Elhwuegi A. The effect of GABAmimetics on the duration of immobility in the forced swim test in albino mice. Libyan J Med 2014; 9: 23480.
Petty F, Trivedi MH, Fulton M, Rush AJ. Benzodiazepines as antidepressants: does GABA play a role in depression? Biol Psychiatry 1995; 38: 578–591.
Guidotti A, Dong E, Matsumoto K, Pinna G, Rasmusson AM, Costa E. The socially-isolated mouse: a model to study the putative role of allopregnanolone and 5alpha-dihydroprogesterone in psychiatric disorders. Brain Res - Brain Res Rev 2001; 37: 110–115.
Khisti RT, Chopde CT, Jain SP. Antidepressant-like effect of the neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one in mice forced swim test. Pharmacol Biochem Behav 2000; 67: 137–143.
Rodriguez-Landa JF, Contreras CM, Bernal-Morales B, Gutierrez-Garcia AG, Saavedra M. Allopregnanolone reduces immobility in the forced swimming test and increases the firing rate of lateral septal neurons through actions on the GABAA receptor in the rat. J Psychopharmacol 2006; 21: 76–84.
Fischell J, Van Dyke AM, Kvarta MD, LeGates TA, Thompson SM. Rapid antidepressant action and restoration of excitatory synaptic strength after chronic stress by negative modulators of alpha5-containing GABAA receptors. Neuropsychopharmacology 2015; 40: 2499–2509.
Fava M, Schaefer K, Huang H, Wilson A, Iosifescu DV, Mischoulon D et al. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. J Clin Psychiatry 2011; 72: 473–479.
Ahmed N, Thornalley PJ. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab 2007; 9: 233–245.
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813–820.
McMurray KMJ, Distler MG, Sidhu PS, Cook JM, Arnold La, Palmer AA et al. Glo1 inhibitors for neuropsychiatric and anti-epileptic drug development. Biochem Soc Trans 2014; 42: 461–467.
Distler MG, Palmer AA. Role of Glyoxalase 1 (Glo1) and methylglyoxal (MG) in behavior: recent advances and mechanistic insights. Front Genet 2012; 3: 250.
Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59: 1116–1127.
Polyakova M, Stuke K, Schuemberg K, Mueller K, Schoenknecht P, Schroeter ML. BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. J Affect Disord 2015; 174: 432–440.
Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15: 7539–7547.
Zhou W, Wang N, Yang C, Li XM, Zhou ZQ, Yang JJ. Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Eur Psychiatry 2014; 29: 419–423.
Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng P et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011; 475: 91–95.
Pascual-Brazo J, Castro E, Díaz A, Valdizán EM, Pilar-Cuéllar F, Vidal R et al. Modulation of neuroplasticity pathways and antidepressant-like behavioural responses following the short-term (3 and 7 days) administration of the 5-HT4 receptor agonist RS67333. Int J Neuropsychopharmacol 2012; 15: 631–643.
Di Loreto S, Zimmitti V, Sebastiani P, Cervelli C, Falone S, Amicarelli F. Methylglyoxal causes strong weakening of detoxifying capacity and apoptotic cell death in rat hippocampal neurons. Int J Biochem Cell Biol 2008; 40: 245–257.
Distler MG, Gorfinkle N, Papale LA, Wuenschell GE, Termini J, Escayg A et al. Glyoxalase 1 and its substrate methylglyoxal are novel regulators of seizure susceptibility. Epilepsia 2013; 54: 649–657.